Kidney Medullary Carcinoma

P=N/A, N=8000, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Mar 2026

Postoperative recovery was uneventful, and the cat remained normotensive and clinically stable at one year, with chronic kidney disease managed medically. This case underscores the diagnostic complexity of feline pheochromocytoma and highlights the importance of integrating imaging, histopathology, and immunohistochemistry, as chromogranin A negativity does not exclude this diagnosis.

Addition of ixazomib to gemcitabine plus doxorubicin modestly increased radiographic response but did not extend disease control in an all-comer biomarker-unstratified RMC cohort. The integrated correlatives nominate mechanisms and biomarkers to guide future mechanism-directed trials in RMC.

We report the case of a woman with metastatic SMARCB1-deficient renal medullary carcinoma who developed acute hypoxic respiratory failure shortly after receiving combination gemcitabine and carboplatin. Discontinuation of gemcitabine and initiation of systemic steroids resulted in significant clinical improvement. This case highlights the diagnostic challenges of gemcitabine pulmonary toxicity in patients with metastatic lung disease and concurrent viral infection.

P=N/A, N=0, Available, Regeneron Pharmaceuticals

In this group, each tumour has its own genetics, whose molecular mechanisms are increasingly well understood, with fusions, tandem duplications or gene mutations which can help the pathologist to achieve to an accurate diagnosis in each morphological context. In some situations, the identification of these molecular alterations may lead to a targeted treatment.

P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Feb 2028 --> Jun 2028

Therapeutic advances are reshaping the management of nccRCC, with IO/TKI regimens and histology-specific therapies showing promise. Continued integration of molecular classification, rare subtype-specific trials, and international collaboration will be essential to establish evidence-based treatment standards for this diverse and understudied population.

P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center

P2, N=314, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

Given its highly aggressive nature, early and accurate diagnosis is crucial. Pathologists must integrate clinical history, morphological characteristics, immunophenotype for a comprehensive diagnosis.

P2, N=157, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028